Skip to content
MedsAcross

Medicine

Fluticasone Propionate Diskus 250 mcg inhalation powder

Fluticasone propionate · Inhalation · Prasco Laboratories
Available on requestPrescription onlyUS FDA

Fluticasone Propionate Diskus 250 mcg inhalation powder is a prescription medicine containing Fluticasone propionate for inhalation use, marketed by Prasco Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at room temperature between 68°F and 77°F (20°C and 25°C), excursions…

Key facts

Active ingredient (INN)
Fluticasone propionate
Brand
Fluticasone Propionate Diskus
Strength
250 mcg
Dosage form
Inhalation powder
Route
Inhalation
Packs
1 inhaler
Marketing authorisation holder
Prasco Laboratories
Manufacturers
Prasco LaboratoriesSportpharm
Origin register
US FDA, United States
Storage
Store at room temperature between 68°F and 77°F (20°C and 25°C), excursions permitted from 59°F to 86°F (15°C to 30°C). Store in a dry place away from direct heat or sunlight. Fluticasone Propionate DISKUS should be stored inside the unopened moisture-protective foil pouch and only removed from the pouch immediately before initial use.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.32Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
30 October 2023
Identifiers
RxCUI 896018, 896021, 896025DailyMed set ID 44d009ba-d4b8-410f-b2bc-71ab2d05ac9e, 348cbd8c-edeb-499c-961d-3aeb5cc2cef1NDC 66993-792, 85766-237Application NDA020833

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 inhaler in 1 carton / 60 powder, metered in 1 inhaler66993-792-97Prasco Laboratories30 October 2023
1 inhaler in 1 carton / 60 powder, metered in 1 inhaler85766-237-60Sportpharm2 July 2026

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 14 December 1990Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Fluticasone propionate

Clinical summary

Fluticasone propionate is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older, among other approved uses. MedsAcross supplies Fluticasone propionate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Fluticasone propionate

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Fluticasone Propionate Diskus 250 mcg inhalation powder for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.